GlassScriptPhysician profile
David J Mcdonald
NPI 1104846815
$16,842.12
in general payments reported to CMS, 2019-2025
67 companies · $1,744 in 2025
The $1,744 reported for 2025 was less than what a typical Diagnostic Neuroimaging (Psychiatry & Neurology) provider received nationally (typical 2025 total: $1,744).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,961 · 2020: $1,605 · 2021: $2,167 · 2022: $2,669 · 2023: $3,007 · 2024: $2,688 · 2025: $1,744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,331 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,331.04 |
| Education | $108.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,000.57 | 2019-2025 | |
| Eisai INC. | $1,441.55 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,071.00 | 2019-2025 | |
| Mdd US Operations, LLC | $909.33 | 2019-2025 | Gocovri, Gocovri |
| Biogen, INC. | $763.28 | 2019-2025 | Skyclarys, Leqembi, Tysabri |
| Emd Serono, INC. | $664.26 | 2019-2025 | Mavenclad |
| Argenx US, INC. | $599.98 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Csl Behring | $552.40 | 2020-2024 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $537.09 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Pfizer INC. | $494.16 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $476.56 | 2019-2024 | Ultomiris, Soliris |
| Ucb, INC. | $473.81 | 2019-2025 | Briviact, Rystiggo |
| Genzyme Corporation | $449.50 | 2019-2024 | |
| Sk Life Science, INC. | $432.31 | 2020-2025 | |
| Lilly USA, LLC | $417.88 | 2021-2025 | Amyvid, Kisunla, Emgality |
Show all 66 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mcdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.